



Immunomic Therapeutics, Inc., Announces Bernard C. Rudnick's Nomination to the Board of Directors

/EINPresswire.com/ FOR IMMEDIATE RELEASE

Hershey, PA, & Rockville, MD April 10th, 2013 – [Immunomic Therapeutics, Inc.](#), ("ITI," Hershey, PA), a leader in developing novel allergy immunotherapies, announced today the nomination of Bernard C. Rudnick to its Board of Directors. The nomination of Mr. Rudnick to the Board occurs at a pivotal time for ITI, having recently completed its first-in-man Phase I clinical study for [JRC-LAMP-vax](#).

"Bernard C. Rudnick has extensive experience in start-ups, a long track record and success in biotech ventures. His history of exceptional corporate governance is a great asset for Immunomic Therapeutics, now that we are a clinical stage biotechnology company", remarked Bill Hearl, ITI's Founder and CEO.

Mr. Rudnick is founder and managing partner of CapGenic Advisors, LLC He brings over 36 years of experience in executive-level strategy, finance, and management. He has extensive knowledge in merger, acquisition, capital formation and licensing leadership with companies ranging from start-up to Fortune 50. He currently advises companies in the clinical software space, therapeutic, medical device, and in the cell line engineering areas. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now MRGE) as well as a number of early stage life sciences companies.

Currently, Mr. Rudnick is a director of Otosound, Benten Bioservices, director and CFO of Immunomic Therapeutics, CFO and Director of Genomic Expression. He founded one of the nation's leading entrepreneurial programs (MADV) at the Fox School of Business, and is an active member of several syndicated angel capital groups. Mr. Rudnick's entrepreneurial career includes a number of startups, three of which grew to over \$60 million in revenue before exiting. He has been instrumental in companies' successes, and has raised over \$700 million for biotechnology companies.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company with lab facilities in Rockville, MD and process-development plant in Hershey, PA. ITI is developing next generation vaccines based on the patented LAMP Technology. Our [LAMP-vax™ vaccine platform](#) significantly increases the effectiveness of the immune response to nucleic acid

vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.

x x x

CONTACT:

Dr. Bill Hearl, President / CEO

Phone: 1-717-327-1919

Immunomix@gmail.com Immunomic Therapeutics, Inc.

1214 Research Blvd, Suite 201

Hershey, PA 17036

E-mail: info@immunomix.com

Web: www.immunomix.com

Press Release: B Rudnick nominated to BOD

Issued 04/15/2013

This press release can be viewed online at: <https://www.einpresswire.com/article/146358446>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.